Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;28(4):269-72.
doi: 10.1016/j.beha.2015.10.015. Epub 2015 Oct 21.

Hairy cell leukemia: Past, present and future

Affiliations
Review

Hairy cell leukemia: Past, present and future

Bartlomiej M Getta et al. Best Pract Res Clin Haematol. 2015 Dec.

Abstract

This brief review highlights the sequence of therapeutic milestones and advances in our understanding of the biology of hairy cell leukemia (HCL) with a focus on recent molecular findings and how these may be applied to improve disease outcomes in the future. Targeted therapy is discussed in the context of the recently identified BRAF mutation and other genetic findings.

Keywords: BRAF; Hairy cell leukemia; Vemurafenib.

PubMed Disclaimer

Conflict of interest statement

None.

Similar articles

Cited by

References

    1. Morton LM, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276. - PMC - PubMed
    1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609–30. - PubMed
    1. Tiacci E, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15. - PMC - PubMed
    1. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16. - PMC - PubMed
    1. Quesada JR, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310(1):15–8. - PubMed

MeSH terms